熱門資訊> 正文
Ascendis Pharma提议公开发行ADSS
2024-09-19 04:17
- Ascendis Pharma A/S (ASND) commenced an underwritten public offering of $300M of American Depositary Shares, each of which represents one ordinary share of Ascendis.
- In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $45M of ADSs at the public offering price, less the underwriting commissions.
- Source: Press Release
More on Ascendis Pharma
- Ascendis Challenges BioMarin, But Market Response Seems Excessive
- Ascendis Pharma Takes A Big Price Cut On Skytrofa
- Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript
- BioMarin off 17% as Ascendis data seen as threat to Voxzogo
- Ascendis raised to outperform by Oppenheimer ahead of drug launch
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
